Abundance Potential

Assessment scope

Development

UHRF1 as a candidate prognostic biomarker for adult T-cell leukemia/lymphoma (ATLL); the cell-line experiments are supporting biological evidence, not a separate clinical treatment development.

Baseline

The article describes current ATLL prognostic assessment as relying largely on clinical staging; no established clinical UHRF1 test or use is shown.

Population

Adults with ATLL; the reported cohort included 72 patients. Findings do not establish applicability to children or other cancers.

Geography

Patients were reported from Ningde Municipal Hospital and Fujian Medical University Union Hospital in China, although the paper inconsistently describes the analysis as single-center.

Target assumptions

Potential benefits depend on independent validation, a reliable assay and threshold, added value beyond clinical staging, and evidence that using the result improves care. These conditions have not been demonstrated.

Five dimensions

Human wellbeing

1/4 · If validated and shown to inform care, an additional prognostic marker could provide limited benefit for adults with ATLL. The cohort shows an association with poorer survival, not that testing improves decisions or patient outcomes. Sources: evidence-2003, evidence-2007

Affordability and access

Unknown · The supplied evidence does not establish assay costs, availability, or access to testing or any resulting care.

Reach and fairness

Unknown · The evidence comes from a small adult ATLL cohort with inconsistent reporting of the study centers; reach across populations and fairness of access were not assessed. Sources: evidence-2007

Environment and resources

Unknown · The supplied evidence does not assess environmental effects or resource use.

Scientific capability

2/4 · The cohort association and knockdown experiments in two ATLL cell lines add meaningful but bounded evidence for studying UHRF1 in ATLL. The mechanism remains unresolved, and broader validation is needed. Sources: evidence-2003, evidence-2004, evidence-2005, evidence-2007

Evidence, confidence and timing

Evidence maturity

Finding: Laboratory. Evidence includes a retrospective patient cohort and shRNA experiments in two cell lines. The supplied material does not show a validated clinical test or deployed use.

Societal benefit: Early speculative. Prognostic information could help care if validated and shown to change decisions, but no clinical utility or patient benefit is demonstrated.

Confidence: Low. Support rests on a retrospective cohort of 72 patients, relatively short follow-up, and two cell lines. The authors call for larger multi-center validation, report an inconsistency about study centers, and state that patient data are restricted.

Conditional time horizon: Unknown. The supplied material gives no timeline for validation or clinical use, and the authors identify further validation as necessary.

Possible benefits

• If independently validated and shown to add useful information to clinical staging, UHRF1 could offer clinicians another way to assess prognosis for adults with ATLL; improved decisions or outcomes have not been shown. Sources: evidence-2003, evidence-2007
• The cell-line findings could guide further research into ATLL biology and possible therapeutic relevance, but do not establish a treatment benefit. Sources: evidence-2004, evidence-2005

Risks and possible harms

• Using an unvalidated marker in care could misclassify patients and lead to unsupported treatment or monitoring decisions. Affected groups: Adults with ATLL and the clinicians caring for them. Sources: evidence-2003, evidence-2007
• Treating cell-line knockdown results as evidence of a patient treatment effect could create unsupported expectations about benefit. Affected groups: People with ATLL and their caregivers. Sources: evidence-2004

Distribution and adoption

Who might be excluded

• Children and people with cancers other than ATLL are outside the reported patient cohort and tested cell lines; applicability to them is not established. Sources: evidence-2003, evidence-2004

Adoption barriers

• The retrospective, relatively small cohort, short follow-up, and reported need for larger multi-center validation limit clinical adoption. Sources: evidence-2007
• The article reports that supporting patient data are restricted and not publicly available, limiting independent reanalysis. Sources: evidence-2008
• The evidence does not establish a validated clinical assay, decision threshold, or added clinical utility. Sources: evidence-2003, evidence-2007

Assumptions and conditions that could change the assessment

• The prognostic association will replicate in larger, multi-center cohorts and remain useful across relevant patient groups. Sources: evidence-2007
• A reliable assay and threshold can add information beyond clinical staging and lead to better care decisions. Sources: evidence-2003, evidence-2007
• Independent prospective multi-center validation, including evidence on durability and performance across patient groups, would strengthen the case for clinical use. Sources: evidence-2007
• Evidence that the assay is reliable, adds clinical utility, and can be accessed fairly would change the access and reach assessments. Sources: evidence-2007
• Replication in additional ATLL models, primary cells, and in vivo studies would change the assessment of therapeutic relevance. Sources: evidence-2004, evidence-2007

Citations

1. evidence-2003 · Elevated UHRF1 predicts unfavorable clinical outcomes in adult T-cell leukemia/lymphoma: Clinicopathological analysis and preliminary in vitro observations · Y; i; n; g; ; L; i; n · 10.1371/journal.pone.0362674 · Captured publisher article text · Open source
2. evidence-2004 · Elevated UHRF1 predicts unfavorable clinical outcomes in adult T-cell leukemia/lymphoma: Clinicopathological analysis and preliminary in vitro observations · Y; i; n; g; ; L; i; n · 10.1371/journal.pone.0362674 · Captured publisher article text · Open source
3. evidence-2005 · Elevated UHRF1 predicts unfavorable clinical outcomes in adult T-cell leukemia/lymphoma: Clinicopathological analysis and preliminary in vitro observations · Y; i; n; g; ; L; i; n · 10.1371/journal.pone.0362674 · Captured publisher article text · Open source
4. evidence-2007 · Elevated UHRF1 predicts unfavorable clinical outcomes in adult T-cell leukemia/lymphoma: Clinicopathological analysis and preliminary in vitro observations · Y; i; n; g; ; L; i; n · 10.1371/journal.pone.0362674 · Captured publisher article text · Open source
5. evidence-2008 · Elevated UHRF1 predicts unfavorable clinical outcomes in adult T-cell leukemia/lymphoma: Clinicopathological analysis and preliminary in vitro observations · Y; i; n; g; ; L; i; n · 10.1371/journal.pone.0362674 · Captured publisher article text · Open source